|
|
The World Market for Antidepressants, 2006Published by: Visiongain Published: Sep. 12, 2005 - 112 Pages Table of Contents
LIST OF TABLES Table 1.1 Leading Drugs in the Antidepressant Market, 2005 Table 2.1 Main Causes of Disability in Disability Adjusted Life Years (DALY) for Adults 15-59, 2002 Table 3.1 Top Ten Antidepressants in the World and their Mode of Action, 2005 Table 4.1 World Revenues ($m) for Antidepressant Drugs, 2003-2010 Table 4.2 Patent Expiry for Antidepressants and Selected Formulations, 2005 Table 4.3 FDA Approved Indications for Antidepressants, 2005 Table 4.4 Patent Expiry for Extended Release Formulations (US patents), 2005 Table 4.5 World Zoloft Revenues ($m), 2003-2010 Table 4.6 World Paxil Revenues ($m), 2003-2010 Table 4.7 World Celexa Revenues ($m), 2003-2010 Table 4.8 World Lexapro Revenues ($m), 2003-2010 Table 4.9 World Prozac Revenues ($m), 2003-2010 Table 4.10 World Luvox Revenues ($m), 2003-2010 Table 4.11 World Effexor Revenues ($m), 2003-2010 Table 4.12 World Cymbalta Revenues ($m), 2003-2010 Table 4.13 World Wellbutrin Revenues ($m), 2003-2010 Table 4.14 World Remeron Revenues ($m), 2003-2010 Table 5.1 US Revenues ($m) for Antidepressants, 2002-2004 Table 5.2 US Prescription Numbers (m) for Antidepressants, 2002-2004 Table 5.3 Percentage of Prescriptions for Generic and Branded Antidepressants (US) 2002-2004 Table 5.4 Average Cost ($/unit) of Antidepressant Prescriptions (US), 2004 Table 5.5 Generic Prescriptions (US) for Leading Antidepressants, 2004 Table 5.6 Generic Revenues (US) for Leading Antidepressants, 2004 Table 6.1 Major Antidepressant Drug Classes and Common Side Effects, 2005 Table 7.1 Triple Uptake Inhibitors in the Developmental Pipeline, 2005 Table 7.2 5HT Agonists in the Developmental Pipeline, 2005 Table 7.3 Neurokinin Receptor Antagonists in the Developmental Pipeline, 2005 Table 7.4 CRF Receptor Antagonists in the Developmental Pipeline, 2005 Table 7.5 Antidepressants with Other Modes of Action in the Developmental Pipeline, 2005 Table 8.1 The Substantial Influence of Patent Loss on the Antidepressant Market, 2005 LIST OF FIGURES Figure 4.1 Total World Revenues for Antidepressants, 2003-2010 Figure 4.2 World Revenues for Leading Antidepressants, 2004 and 2010 Figure 4.3 Market Share (%) for Antidepressants, 2004 Figure 4.4 Market Share (%) for Antidepressants, 2010 Figure 4.5 Cost of Antidepressants, 2005 Figure 4.6 Price Comparison of Branded and Generic Antidepressants, 2005 Figure 4.7 World Market Share (%) by Drug Class, 2004 Figure 4.8 World Market Share (%) by Drug Class, 2010 Figure 4.9 World Revenues ($m) for Zoloft, 2003-2010 Figure 4.10 World Revenues ($m) for Paxil, 2003-2010 Figure 4.11 World Revenues ($m) for Celexa and Lexapro, 2003-2010 Figure 4.12 World Revenues ($m) for Prozac, 2003-2010 Figure 4.13 World Revenues ($m) for Luvox, 2003-2010 Figure 4.14 World Revenues ($m) for Effexor, 2003-2010 Figure 4.15 World Revenues ($m) for Cymbalta, 2003-2010 Figure 4.16 World Revenues ($m) for Wellbutrin, 2003-2010 Figure 4.17 World Revenues ($m) for Remeron, 2003-2010 Figure 4.18 World Market Share (%) by Company, 2004 Figure 4.19 World Market Share (%) by Company, 2010 Figure 5.1 World Revenues ($m) for Antidepressant by Country/Region, 2004 Figure 5.2 Revenues ($m) for US Antidepressants, 2004 Figure 5.3 Prescriptions for US Branded and Generic Antidepressants, 2002-2004 Figure 5.4 US Prescription Trends for Antidepressants, 2002-2004 Figure 5.5 Percentage of US Prescriptions for Generic and Branded Antidepressants, 2002 Figure 5.6 Percentage of US Prescriptions for Generic and Branded Antidepressants, 2004 Figure 5.7 Average Cost ($/unit) of Antidepressants, 2004 Figure 5.8 Willingness to Seek Help for Mental Health Disorders in Europe Figure 5.9 World Revenue ($m) for Antidepressant by Country in Europe, 2004 Figure 6.1 A SWOT Chart for the Antidepressant Market, 2005 Figure 8.1 Antidepressant Market in Relation to Major Patent Losses, 2004-2010 Organisations listed: Alphapharm Amarin Pharmaceuticals Inc Astellas Pharma AstraZeneca Azko Nobel Bristol-Myers Squibb Clinical Data Inc. Dainippon Pharmaceutical Eli Lilly Fabre-Kramer Pharmaceuticals Forest Laboratories GSK Hoffmann-La Roche IVAX Johnson & Johnson Lundbeck A/S Merck & Co. Merck KgaA Neurogen Corp. Novartis NPS Ono Pharma USA Inc Organon USA Par Pharmaceutical Pfizer Predix Pharmaceuticals Sanofi-Aventis Schwabe Pharmaceuticals Sepracor Inc Servier Verispan Walgreens Wyeth AbstractIn 2004 total world revenues for branded antidepressant drugs was worth over $13bn, but with only ten drugs on the market. However, nine out of these ten drugs faces a loss of patent in the period 2006-2010.Please Note: Reports are sold based on the user licenses indicated. The Publisher delivers the report in Flash format via the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order, the Publisher will email the client with information on accessing their purchase. Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||